Inhaled Treprostinil for Pulmonary Hypertension
(EPIH IIT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional outcomes in adults with interstitial lung disease or connective tissue disease and exercise-induced pulmonary hypertension. Participants will receive inhaled treprostinil plus standard care or standard care alone and will be followed for 6 months, with an optional extension to 12 months.
Who Is on the Research Team?
Ashish Rai Rai, MD
Principal Investigator
Valley Health System
Are You a Good Fit for This Trial?
This trial is for adults with interstitial lung disease or connective tissue disease who develop high blood pressure in the lungs during exercise. Participants should not have other major health issues that would prevent safe participation.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Treprostinil
Trial Overview
The study compares inhaled treprostinil plus standard care versus standard care alone to see if it helps improve lung blood flow and physical ability. Participants are followed for at least 6 months, possibly up to a year.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants receive inhaled treprostinil (Tyvaso) in addition to standard disease-specific care.
Participants receive standard disease-specific care without inhaled treprostinil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Valley Health System
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.